IQVIA™ (NYSE:IQV) and Genomics England are collaborating to develop a platform that will connect clinical and de-identified genomics data to accelerate treatment advancements for patients. This alliance will enable faster and more efficient drug research, more robust evidence to support treatment value, and greater access to personalised medicines.
Jon Resnick, president, IQVIA Real-World and Analytics Solutions said, “Our collaboration advances the analysis of these complex datasets, which could accelerate the discovery of precision therapies, improve access and health outcomes, and deliver upon our Human Data Science vision.”
“Izy Capital is a rare breed of early stage venture and advisory that understands the complexities of modern financing, entrepreneurship and global delivery. Their reach is extraordinary, as is their vision. I never feel that Dave and the team have anything other than our interests at the core of everything they do”
Geryn Evans, CEO Project Blu
“David and the whole Izy Capital team are, simply, great partners. Approachable, direct, and always mindful of the risk/reward relationship in our growth, their vision, modelling and process management is exemplary. Dave always sees the bigger picture and endgame and above all deals with everyone with a level of humility which is so refreshing”
Phil Davies, CEO Flyform
Izy and more specifically David has enabled us to be laser focussed on delivery and customer segmentation. In a competitive market segment Dave has guided us to create a value proposition and outcomes orientated approach that is aligned with our mission of helping 500m to be more Mindful in their approach to life and others by 2025